The Italian pharmaceutical sector begins to suffer. Among the first signs of "strong criticality" highlighted by Farmindustria, during the public meeting held in Rome, was the slowdown in investments which went from an annual growth of 6% between 2002 and 2007 to one of 1.3% in 2009. C 'then there is the inversion of the foreign balance of medicines which, after a decade of positives, is now negative for 720 million, with a trend confirmed also in the first months of 2010. Pharmaceutical companies and their workers must also deal with the reduction of employment by 7,200 units between 2006 and 2009 (-10%). All this without forgetting - Farmindustria points out - that the per capita pharmaceutical expenditure in Italy is 184 euros, against 267 in the large European countries. A figure that is even down compared to 2001. The country - warns the association of drug entrepreneurs - cannot lose a quality industry which has 67,500 employees, 90% graduates or graduates, 54% of production for export, 2.3 billion euros of investments per year, and which determines the 43% of exports of the country's "science-based" sectors and is the first of the Italian hi-tech sectors by world market share.
DoctorNews – 24 June 2010 – Year 8, Number 115
Dompé, more European controls on the import of generics
A European inspection body that carries out checks on all the production sites of pharmaceutical companies that import medicines into the old continent, especially generic ones, to guarantee the safety and health of citizens. The president of Farmindustria, Sergio Dompé, hoped for its establishment, who spoke about it during the press conference organized in Rome on the occasion of the 2010 public meeting of the association of drug manufacturers. «The European legislation on generics is sacrosanct – said Dompé – and there is no request to modify it. But Europe, large as it is today, needs an ad hoc inspection body. No one here does it like in the United States, where the Food and Drug Administration carries out inspections in all the manufacturing plants in the world that export drugs to the United States». The president of Farmindustria also recalled that «the choice of a generic drug, in my opinion, should fall on one produced by companies that have decades of experience. It is clear that in the face of a minimal price difference, if I am faced with Bayer's acetylsalicylic acid, which has been producing it for a hundred years, I will prefer it to that of company "X", of which I know nothing».
Farmindustria, Italy third producer in the EU
Italy is the third largest drug producer in Europe after Germany and France, and the fifth in the world, with the USA and Japan in the first two places. This was highlighted by Farmindustria on the occasion of the public assembly "Recognizing the value, fighting waste - Quality of the drug industry and efficiency of the health system", which was held yesterday in Rome. Pharmaceuticals – underlines Farmindustria – are therefore a strategic lever for the Italian economy and for its relaunch, as demonstrated by the key figures for 2009: 22.6 billion euro of production, the 54% aimed at exports; 12.2 billion euros of total exports, of which 9.3 of medicines; over 4 billion euros of salaries and contributions to which 1.9 billion of related activities are added; 1.3 billion euros
